Articles

Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of Hematology, Oncology and Tumor Immunology, Charité Universitätsmedizin Berlin, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, USA
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
Institute for Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität (LMU), München, Germany
Institute for Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität (LMU), München, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, USA
Department of Molecular Medicine and Pathology, The University of Auckland, New Zealand
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Medicine II, Goethe University Hospital, Frankfurt, Germany
Department of Hematology, University Hospital Schleswig-Holstein Campus Kiel, Germany
German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of Hematology, Oncology and Tumor Immunology, Charité Universitätsmedizin Berlin, Germany
Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
Department of Medicine II, Goethe University Hospital, Frankfurt, Germany
Vol. 102 No. 1 (2017): January, 2017 https://doi.org/10.3324/haematol.2015.136366